Avadel Cash And Short Term Investments from 2010 to 2024

AVDL Stock  USD 15.13  0.12  0.79%   
Avadel Pharmaceuticals Cash And Short Term Investments yearly trend continues to be quite stable with very little volatility. The value of Cash And Short Term Investments are projected to decrease to about 72.6 M. Cash And Short Term Investments is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. View All Fundamentals
 
Cash And Short Term Investments  
First Reported
1996-03-31
Previous Quarter
105.1 M
Current Value
88.8 M
Quarterly Volatility
61 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Avadel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avadel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 10.4 M or Selling General Administrative of 159.3 M, as well as many indicators such as Price To Sales Ratio of 38.26, Dividend Yield of 0.0 or PTB Ratio of 13.55. Avadel financial statements analysis is a perfect complement when working with Avadel Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.

Latest Avadel Pharmaceuticals' Cash And Short Term Investments Growth Pattern

Below is the plot of the Cash And Short Term Investments of Avadel Pharmaceuticals PLC over the last few years. Short Term Investments is an account in the current assets section of Avadel Pharmaceuticals balance sheet. This account contains Avadel Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Avadel Pharmaceuticals PLC fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. Avadel Pharmaceuticals' Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avadel Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Cash And Short Term Investments10 Years Trend
Slightly volatile
   Cash And Short Term Investments   
       Timeline  

Avadel Cash And Short Term Investments Regression Statistics

Arithmetic Mean90,598,994
Geometric Mean62,077,669
Coefficient Of Variation68.25
Mean Deviation46,755,074
Median94,075,000
Standard Deviation61,834,410
Sample Variance3823.5T
Range214.4M
R-Value0.54
Mean Square Error2916.5T
R-Squared0.29
Significance0.04
Slope7,467,648
Total Sum of Squares53528.9T

Avadel Cash And Short Term Investments History

202472.6 M
2023105.1 M
202296.5 M
2021157.2 M
2020221.4 M
201964.2 M
201899.9 M

About Avadel Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Avadel Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Avadel Pharmaceuticals investors use historical funamental indicators, such as Avadel Pharmaceuticals's Cash And Short Term Investments, to determine how well the company is positioned to perform in the future. Although Avadel Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Avadel Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Avadel Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Avadel Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Avadel Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash And Short Term Investments105.1 M72.6 M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Avadel Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Information and Resources on Investing in Avadel Stock

When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports:
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.82)
Revenue Per Share
0.633
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.55)
Return On Equity
(7.80)
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.